Entwistle
Carole Entwistle, Geneva SZ
Patent application number | Description | Published |
---|---|---|
20150149318 | System and Method For Determining and Displaying the Metabolic Energy of Skin Cells - The present invention is related to a computer-based system and method for determining and displaying the metabolic energy of skin cells of an individual, based on a set of biological data collected from the individual, including but not limited to: skin wrinkling, skin texture, skin pigmentation, skin hydration, age, UV exposure, and/or health habits. Particularly, the present invention is useful for counseling consumers of cosmetic products on sales counters regarding the metabolic energy of their skin and making corresponding recommendations for appropriate cosmetic products that will improve their skin metabolic energy. | 05-28-2015 |
David Andrew Entwistle, Sandwich GB
Patent application number | Description | Published |
---|---|---|
20120208830 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-am- ino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide - The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I). | 08-16-2012 |
20120214827 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-am- ino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide - The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I). | 08-23-2012 |
Ian Roger Entwistle, Lancashire GB
Patent application number | Description | Published |
---|---|---|
20100032442 | DISPENSING WIPES - The invention relates to the dispensing of wipes ( | 02-11-2010 |
John Entwistle, Christiansburg, VA US
Patent application number | Description | Published |
---|---|---|
20090246767 | Compositions and methods for detecting Cryptococcus neoformans - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 10-01-2009 |
20120015362 | Compositions and methods for detecting cryptococcus neoformans - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 01-19-2012 |
Jon S. Entwistle, Las Vegas, NV US
Patent application number | Description | Published |
---|---|---|
20130339573 | OPTIMIZING WRITE PERFORMANCE TO FLASH MEMORY - Embodiments relate to optimizing write performance of a flash device. Aspects include receiving a request to evict a plurality of pages from a main memory and determining a block size for the flash device. Aspects also include grouping the plurality of pages from the main memory into a move specification block, wherein a size of the move specification block is the block size and writing the move specification block to the flash device. The block size being determined based on one or more operational characteristics of the flash device. | 12-19-2013 |
Joycelyn Entwistle, Winnipeg CA
Patent application number | Description | Published |
---|---|---|
20100254982 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof. | 10-07-2010 |
20120128723 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof. | 05-24-2012 |
20130217865 | Tumor Specific Antibody - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention. | 08-22-2013 |
20150018526 | Cytotoxins comprising modified bouganin toxin for the treatment of cancer - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 01-15-2015 |
Joycelyn Entwistle, Manitoba CA
Patent application number | Description | Published |
---|---|---|
20080219994 | MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 09-11-2008 |
20100254964 | Modified Bouganin Proteins, Cytotoxins and Methods and Uses Thereof - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 10-07-2010 |
Keith Entwistle, Cumming, GA US
Patent application number | Description | Published |
---|---|---|
20110040748 | Technical Electronic Discovery Action Model - Embodiments of the present invention provide for an end-to-end system and method for identifying custodians, preserving, collecting, processing, reviewing, analyzing, producing, presenting, and dispositioning data responsive to a legal discovery request. | 02-17-2011 |
Lorne Entwistle, Bury GB
Patent application number | Description | Published |
---|---|---|
20140196257 | RELEASABLE CONNECTOR - A releasable connector is provided, in particular, for connecting rods or bars together, especially rods and bars forming, part of temporary fencing panels, or as a pair of handcuffs. The connector comprises at least one strap that projects from a locks The strap is adapted to be wrapped around part of a first item and the connector is provided with a second means whereby it can be secured to a second item so that the first and second items can be connected together. The lock is located in an aperture defined by the connector adjacent a channel into which a free end of the strap may be inserted. The lock comprises a rotatable barrel that defines at least one projection which on rotation of the barrel engages the strap when it is within the channel to secure the strap in position. | 07-17-2014 |
Mark D. Entwistle, Feasterville-Trevose, PA US
Patent application number | Description | Published |
---|---|---|
20150192676 | LiDAR System Comprising A Single-Photon Detector - A method for developing a map of objects in a region surrounding a location is disclosed. The method includes interrogating the region along a detection axis with a series of optical pulses and detecting reflections of the optical pulses that originate at objects located along the detection axis. A multi-dimensional map of the region is developed by scanning the detection axis about the location in at least one dimension. The reflections are detected via a single-photon detector that is armed using a sub-gating scheme such that the single-photon detector selectively detects photons of reflections that originate only within each of a plurality of zones that collectively define the detection field. In some embodiments, the optical pulses have a wavelength within the range of 1350 nm to 1390 nm, which is a spectral range having a relatively high eye-safety threshold and a relatively low solar background. | 07-09-2015 |
Martin Patrick Entwistle, Albany NZ
Peter M. Entwistle, Bookham GB
Patent application number | Description | Published |
---|---|---|
20090297287 | Cradle arrangement - Transportation of articles such as gas turbine engines can be problematic in view of their size. Traditionally, articles such as gas turbine engines are transported on cradles associated with platforms and bases. It would be desirable to enable manipulation of height and width to allow the assembly of the article, such as a gas turbine engine upon the base to enter apertures such as doors in aircraft fuselages or for minimising width for road or rail or sea transportation. By providing a cradle, having respective cradle sides projecting from a junction in association with a drive mechanism and each side of the cradle coupled to a pivot arm, control of rotation paths can be achieved. Thus, an article such as a gas turbine engine secured to a cradle arrangement can be manipulated between extremes and alternate configurations, defined by rotation paths, through elective association of one or the other of the pivot arms to the cradle and the base. | 12-03-2009 |